South San Francisco-based longevity biotech NewLimit has accelerated its clinical timeline to 2027 after AI-driven research uncovered a novel mRNA-based liver reprogramming therapy that effectively reverses age-related cellular decline in preclinical models. The company, founded by former Calico researcher Jacob Kimmel alongside Coinbase CEO Brian Armstrong and engineer Blake Byers, recently closed a $435 million Series C funding round led by Founders Fund, reaching a valuation of approximately $3.1 billion. The accelerated schedule stems from exceptional late-2025 data demonstrating that NewLimit’s AI-discovered transcription factor combination safely rejuvenates liver cells without triggering tumorigenesis, a critical limitation of traditional Yamanaka factor approaches. In animal trials utilizing an alcohol-induced liver injury model, aged mice receiving the mRNA therapy exhibited metabolic resilience indistinguishable from young controls, eliminating age-dependent sensitivity to ethanol and significantly improving survival rates under repeated stress. Kimmel noted the phenotypic divergence was so pronounced that statistical analysis was unnecessary. NewLimit’s proprietary AI system, Ambrosia, integrates natural language processing and protein sequence modeling to predict how specific gene combinations alter cellular age while preserving cell identity. This high-throughput screening platform has identified over a dozen effective payloads, with the hepatic pipeline serving as the lead candidate. Leveraging established lipid nanoparticle delivery mechanisms, the therapy concentrates in the liver upon intravenous administration. Early validation in humanized mouse models corroborated the findings in standard animals, providing the confidence to fast-track first-in-human Phase I trials targeting patients with early-stage metabolic dysfunction-associated steatotic liver disease. The Australian trial will serve as a proof of concept for potential expansion into chronic kidney disease and age-related inflammation pipelines through endothelial and T-cell reprogramming strategies. The latest capital injection positions NewLimit at the forefront of the AI-native biotech movement, distinguishing it from traditional small-molecule or antibody developers. Rather than designing novel chemical structures, the company’s architecture focuses on computationally mapping epigenetic reversal pathways. Kimmel anticipates a collaborative future between large language model providers and established pharmaceutical manufacturers, echoing the structural evolution of the 1970s biotechnology sector. While capital continues to flow heavily into AI drug discovery, industry leaders maintain that clinical execution, regulatory navigation, and commercialization will require entrenched pharma partnerships rather than vertical integration. NewLimit’s progression from algorithmic discovery to accelerated human trials marks a pivotal step in translating computational biology into measurable longevity interventions.